


Etat des lieux des inclusions et des publications GINECO 2020

Journées scientifiques du GINECO
Mars 2021, Paris




GINECO: WHO'S WHO ?

Centres actifs par type d'établissement 2020



■ Hospital\Anti-cancer center ■ Hospital\Private hospital ■ Hospital\Public hospital

Inclusion 2020 par type d'établissement



■ Hospital\Anti-cancer center ■ Hospital\Private hospital ■ Hospital\Public hospital


#tousensemble



Publications internationales #SOLO2 substudy

IF
7,27

- Tjokrowidjaja A, Lee CK, Friedlander M, Gebiski V, **Gladieff L**, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Manso L, Pisano C, Asher R, Lord SJ, Kim SI, Lee JY, Colombo N, Park-Simon TW, Fujiwara K, Sonke G, Vergote I, Kim JW, **Pujade-Lauraine E**
- **Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy**
- Eur J Cancer 2020 Sep 22;139:59-67




Publications internationales #MILO

- Monk BJ, Grisham RN, Banerjee S, **Kalbacher E**, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, **Ray-Coquard I**, Vergote I.
- **MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum**
- J Clin Oncol 2020 Aug 21



Publications internationales #AGO 2.2

- Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, **Joly F**, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, **Mouret-Reynier MA**, **Costan C**, Meier W, Reinthaller A, Goh JC, **L'Haridon T**, Baron Hay S, Kommoss S, du Bois A, **Kurtz JE**; AGO-OVAR 2.21/ENGOT-ov 18 Investigators.
- **Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial**
- Lancet Oncol. 2020 May;21(5):699-709



Publications internationales #PAOLA BRCA


IF
11,57

- Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillermin E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, **Pujade-Lauraine E, Ray-Coquard I**
- **Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial**
- J Natl Cancer Inst. 2020 Dec 29



Publications internationales #prospectyon

- Selle F, Heudel PE, Hardy-Bessard AC, Pozet A, Meunier J, Gladieff L, Lotz JP, Provansal M, Augereau P, Berton D, Bonichon-Lamichhane N, Orfeuvre H, Pautier P, Kalbacher E, Tazi Y, Spaeth D
- **GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer**
- Anticancer Res. 2020 Jul;40(7):3939-3945



Publications internationales #TMRG

- **Ray-Coquard I**, Harter P, Lorusso D, **Dalban C**, Vergote I, Fujiwara K, **Gladiëff L**, Lück HJ, **Floquet A**, **Chevalier-Place A**, Schnelzer A, Pignata S, **Selle F**, Sehouli J, **Brocard F**, Mangili G, **Pautier P**, De Giorgi U, **Provansal M**, **Heudel PE**
- **Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial**
- JAMA Oncol. 2020 Oct 8





Publications internationales #TMRG

- **C Lenck** , N Chopin , S Gouy , H Bonsang-Kitzis , C Martinez-Gomez , N Radosevic-Robin , S Martin , C Lefeuvre-Plesse , E Lambaudie , E Leblanc , F Guyon , J-M Classe , R Ramanah , F Beurrier , M A Angeles, C Pomel , F Joly T de la Motte Rouge , M Provansal , A Lesoin , A Floquet , D Berton, E Kalbacher, C Chakiba, P Meeus , F Selle , I Treilleux , F Lecuru , P Pautier , I Ray-Coquard
- **The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study**
- Gynecol Oncol 2020 Apr;157(1):78-84



Publications internationales #TMRG

- Chevrot A, Pouget N, Bats AS, Huchon C, Guyon F, Chopin N, Rousset-Jablonski C, Beurrier F, Lambaudie E, Provansal M, Sabatier R, Heinemann M, Ngo C, Bonsang-Kitzis H, Lecuru F, Bailly E, Ferron G, Cornou C, Lardin E, Leblanc E, Philip CA, Ray-Coquard I, Hequet D
- **Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group**
- Gynecol Oncol. 2020 Apr;157(1):29-35



Publications internationales #TMRG

- F Derquin, A Floquet, A C Hardy-Bessard, J Edeline, J P Lotz, J Alexandre, P Pautier, M A Angeles, N Delanoy, C Lefeuvre-Plesse, M Cancel, I Treilleux, P Augereau, V Lavoue, E Kalbacher, D Berton Rigaud, F Selle, C Nadeau, J Gantzer, F Joly, C Guillemet, C Pomel, L Favier, C Abdeddaim, L Venat-Bouvet, M Provansal, M Fabbro, MC Kaminsky, A Lortholary, F Lecuru, I Ray Coquard, T de La Motte Rouge
- **Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network**
- Gynecol Oncol. 2020 Jul 2;S0090-8258(20)32315-5



Publications internationales #CHIVA RT

- Robelin P, Tod M, Colomban O, Lachuer J, Ray-Coquard I, Rauglaudre G, Joly F, Chevalier-Place A, Combe P, Lortholary A, Hamizi S, Raban N, Ferron G, Meunier J, Berton-Rigaud D, Alexandre J, Kaminsky MC, Dubot C, Leary A, Malaurie E, You B
- **Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).**
- Gynecol Oncol. 2020 Jul 22:S0090-8258(20)330



Publications internationales #ESMERALDA

- Hardy-Bessard AC, Brocard F, Clatot F, Lortholary A, You B, Grenier J, Martin-Babau J, Lucas B, Meunier J, Ferrero JM, Savoye AM, Marti A, Despax R, Moullet I, Emile G
- **First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study**
- Breast 2020 Sep 30;54:256-263



Publications internationales #DIVERS

- **Paoletti X**, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, **Pujade-Lauraine E**, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM; Gynecologic Cancer InterGroup (GCIg) Meta-analysis Committee.
- **Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.**
- JAMA Netw Open. 2020 Jan 3;3(1):e1918939




Publications internationales #DIVERS

- Concin N, **Ray-Coquard I**, Glasspool RM, Braicu E, Farrelly L, **Votan B**, Mirza MR, Gonzalez Martin A, Vergote I, Pignata S
- **European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and industry partners - a new Model D for drug and medical device development**
- Int J Gynecol Cancer. 2020 Jun;30(6):730-734



#2020 vs le monde d'avant


Totaux IF GINECO






#Le GINECO ne connaît pas la crise

1200

Patientes incluses dans les études du groupe en 2020



#Podium 2020 !





Jeudi 25 & Vendredi 26 Mars 2021



e-Rencontres Scientifiques du **GINECO**



ARCAGY - GINECO

labellisé par  INSTITUT
NATIONAL
DU CANCER